NCT06279533

Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules

Name: Clinical Trial NCT06279533
Creator: Vigonvita Life Sciences
Keywords: Healthy Subjects, LV232/Placebo, Phase 1, drug, clinical trial, China

Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules in Chinese Healthy Volunteers

Vigonvita Life Sciences·Phase 1·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Healthy Subjects
Drug/Device/Intervention: LV232/Placebo
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Vigonvita Life Sciences
Location: Shanghai, China

Timeline & enrollment

Phase: Phase 1
Start date: Feb 01, 2024
End date: Jul 01, 2024
Enrollment: 48 participants

Primary outcome

Tmax,Cmax,T1/2,AUC0-t,AUC0-24h,AUC0-∞

Summary

This study is divided into two parts: the safety, tolerability, pharmacokinetic profiles of LV232 capsules after multiple ascending doses (hereinafter referred to as PK characteristics of multiple ascending doses study ) and food effect study (hereinafter referred to as FE study). A total of 48 subjects are planned to be enrolled. The two parts of the study can be carried out simultaneously, and there is no order requirement.

ICD-10 classifications

Occupational health examinationSeeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulRoutine child health examinationExamination and observation for other reasons

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06279533
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06279533 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vigonvita Life Sciences and is currently Not yet recruiting. The study focuses on Healthy Subjects. Target enrollment is 48 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.